宋玉丽,张 颐.抑制缺氧诱导因子-1α改善卵巢癌化疗耐药的研究进展[J].肿瘤学杂志,2023,29(3):238-243. |
抑制缺氧诱导因子-1α改善卵巢癌化疗耐药的研究进展 |
Research Progress on Inhibiting Hypoxia-inducible Factor-1α in Improving Chemoresistance of Ovarian Cancer |
投稿时间:2022-12-11 |
DOI:10.11735/j.issn.1671-170X.2023.03.B012 |
|
|
中文关键词: 缺氧诱导因子-1α 卵巢癌 抑制 化疗耐药 |
英文关键词:hypoxia-inducible factor-1α ovarian cancer inhibition chemotherapy resistance |
基金项目:辽宁省应用基础研究计划(2022JH2/101300039);2022年沈阳市科技计划(22-321-33-54);国家卫生健康委医药卫生科技发展研究中心(HDSL202003005) |
|
摘要点击次数: 296 |
全文下载次数: 131 |
中文摘要: |
摘 要:缺氧诱导因子-1α(HIF-1α)是卵巢癌的一个关键调节因子,可通过多种机制促进卵巢癌细胞对化疗的耐药性,并且在一定程度上与卵巢癌患者的不良预后相关。直接或间接抑制HIF-1α的表达或活性的药物可以提高卵巢癌细胞对化疗的反应性。全文就抑制HIF-1α改善卵巢癌化疗耐药方面的研究进展作一综述。 |
英文摘要: |
Abstract: Hypoxia-inducible factor-1α(HIF-1α) is one of the key regulators of ovarian cancer, which can induce the resistance of ovarian cancer cells to chemotherapy through a variety of mechanisms, and is related to the poor prognosis of ovarian cancer patients to a certain extent. Drugs that directly or indirectly inhibit the expression or activity of HIF-1α can improve the responsiveness of ovarian cancer cells to chemotherapy. This article reviews the latest research progress on inhibition of HIF-1α in improving chemotherapy resistance in ovarian cancer. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |